$2.755
-0.208 (-7.55%)收盤時
- High
- 3.000
- Open
- 2.890
- VWAP
- 2.83
- Vol
- 35.29K
- Mkt Cap
- —
- Low
- 2.740
- Amount
- 99.93K
- EV/EBITDA, TTM
- -0.05
Cerenome, Inc., formerly Plus Therapeutics, Inc., is a healthcare company. The Company is focused on central nervous system (CNS) cancers through three business areas: precision diagnostics, targeted radiopharmaceutical therapeutics, and proprietary data analytics. Its subsidiary CNSide Diagnostics, LLC, develops and commercializes proprietary laboratory-developed tests, including the CNSide cerebrospinal fluid (CSF) assay platform, designed to identify, characterize and monitor tumor cells in patients with CNS cancers. Its lead product candidate, rhenium (186Re) obisbemeda (REYOBIQ), is designed for CNS cancers, including recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and pediatric brain cancers (PBC), through direct localized delivery utilizing tissue access methods, including convection-enhanced delivery (CED) and others. Its Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat primary and metastatic solid organ cancers.
AI analysis of CNSY (CNSY)
sellPlus Therapeutics Inc is not a good buy right now due to its declining performance and negative financial indicators. The current price is 2.75, and the stock has experienced a 28.81% decline year-to-date. Additionally, the forward P/E ratio is 0.9696, indicating potential overvaluation given the company's struggles with profitability.
估值指標
CNSY FAQ — answered by Alphio AI
Plus Therapeutics Inc is not a good buy right now due to its declining performance and negative financial indicators. The current price is 2.75, and the stock has experienced a 28.81% decline year-to-date. Additionally, the forward P/E ratio is 0.9696, indicating potential overvaluation given the company's struggles with profitability.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。